Johnson & Johnson Family of Companies

No financial terms were disclosed.

As the number of diagnosed cases of COVID-19 continue to increase across the globe and more and more governments are urging citizens to self-quarantine, the pharmaceutical and life sciences industry continues to work toward the development of a vaccine and therapies for the respiratory infection that was declared a pandemic by the World Health Organization last week. Here’s a biopharma industry overview as of late March 16.

The Breakthrough Therapy Designation is based on data from a Phase I trial of JNJ-6372 alone and in combination with lazertinib, a novel third-generation EGFR TKI in adults with advanced NSCLC.

As the coronavirus outbreak that causes COVID-19 escalates, biopharma companies and government agents are working quickly to develop and test a vaccine, although most estimates are it will take 12 to 18 months before it could get to market.

The BioSpace Ideal Employer Report examined aspects regarding the importance of culture within life sciences organizations.

Now that global responses are fully mobilized, what is being done to identify and develop drugs and vaccines against this novel coronavirus?

The Life Science Women’s Conference is being held on February 19 and 20 at the Tampa Bay Convention Center in Tampa, Florida. Co-founded by Patti Rossman and Steve Fiske, the conference is an opportunity for women to accelerate their life science careers via mentoring, networking and education.

The World Health Organization (WHO) gave the coronavirus that began in Wuhan, China, an official name, COVID-19.

The biotech Hotbed known as Pharm Country, which includes New Jersey, Connecticut, New York Pennsylvania and Rhode Island, is an area of rapid growth and change.